EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Efficacy of redifferentiation therapy in radioactive iodine refractory thyroid cancer: a systematic review and meta-analysis

Emilia Zampella, Valeria Cantoni, Roberta Green, Valeria Gaudieri, Federica Volpicelli, Leandra Piscopo, Mariano Scaglione, Alberto Cuocolo, Michele Klain

European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8177-8188

DOI: 10.1007/s00259-026-08115-7 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 06.08.2026. Verfasst von Emilia Zampella und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Pansini 5, 80131, Naples, Italy. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Iodine Radioisotopes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Napoli Federico II.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To systematically review and meta-analyze the efficacy of redifferentiation therapy in patients with radioactive iodine (RAI)-refractory thyroid cancer.

Methods

PubMed and Scopus databases were comprehensively searched up to January 2026 to identify clinical studies evaluating patients with RAI-refractory thyroid cancer who received targeted therapies to restore radioiodine uptake. Eligible studies reported either the rate of successful iodine re-uptake or treatment response evaluated according to RECIST 1.1 criteria. The primary endpoint was the pooled rate of successful redifferentiation, while secondary endpoints were objective response rate (ORR) and disease control rate (DCR), each stratified by redifferentiation status.

Results

Fifteen studies comprising 234 patients (cohort sizes: 3–33) were included. The pooled rate of successful redifferentiation was 51% (95% confidence interval, CI: 30%-71%), with no significant publication bias. Treatment response according to RECIST 1.1 was evaluated in 11 studies (93 patients). The pooled ORR was 28% (95% CI: 13%-44%) in redifferentiated patients compared to 8% (95% CI: 0%-44%) in non-redifferentiated individuals ( P = 0.33). The pooled DCR was significantly higher, reaching 93% (95% CI: 79%-100%) in redifferentiated patients compared to 54% (95% CI: 15%-91%) in non-redifferentiated patients ( P = 0.04).

Conclusions

In patients with RAI-refractory thyroid tumors, redifferentiation therapy using mitogen-activated protein kinase inhibitors successfully restores radioiodine avidity in approximately half of the cases. Although short-term disease control rates are promising, statistically significant prognostic differences and long-term survival benefits remain to be demonstrated in larger, standardized trials with extended follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsIodine RadioisotopesHumansTreatment Outcome

Stichwörter der Autor:innen

DabrafenibMAPK inhibitorsMeta-analysisRAI-refractory thyroid cancerRadioactive iodineRedifferentiation therapySelumetinibSystematic review

Substanzen

Iodine Radioisotopes

Autor:innen und Institutionen

  • Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Pansini 5, 80131, Naples, Italy.
  • Department of Radiology, University of Sassari, Sassari, Italy.
  • Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Pansini 5, 80131, Naples, Italy. cuocolo@unina.it.
  • IRCCS SYNLAB SDN, Naples, Italy. cuocolo@unina.it.

Förderung

  • Università degli Studi di Napoli Federico II

Zitieren

APA

Zampella, E., Cantoni, V., Green, R., Gaudieri, V., Volpicelli, F., Piscopo, L., Scaglione, M., Cuocolo, A., & Klain, M. (2026). Efficacy of redifferentiation therapy in radioactive iodine refractory thyroid cancer: a systematic review and meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8177-8188. https://doi.org/10.1007/s00259-026-08115-7

Vancouver

Zampella E, Cantoni V, Green R, Gaudieri V, Volpicelli F, Piscopo L, et al. Efficacy of redifferentiation therapy in radioactive iodine refractory thyroid cancer: a systematic review and meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8177-8188. doi:10.1007/s00259-026-08115-7

BibTeX
@article{Zampella2026,
  author = {Zampella, Emilia and Cantoni, Valeria and Green, Roberta and Gaudieri, Valeria and Volpicelli, Federica and Piscopo, Leandra and Scaglione, Mariano and Cuocolo, Alberto and Klain, Michele},
  title = {Efficacy of redifferentiation therapy in radioactive iodine refractory thyroid cancer: a systematic review and meta-analysis},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {13},
  pages = {8177--8188},
  doi = {10.1007/s00259-026-08115-7}
}
Kostenlos starten →